Leading innovators in anti-influenza antibody compositions for the pharmaceutical industry

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Anti-influenza antibody compositions is a key innovation area in pharmaceuticals

Influenza viruses are members of the family orthomyxoviridae. There are four types of influenza viruses: A, B, C, and D. Hemagglutinin (HA), an envelope glycoprotein on the influenza virion enables the virus to enter and spread between cells. This protein also serves as a target for neutralizing antibodies, which can be used to develop for therapeutic as well as diagnostic applications.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 210+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-influenza antibody compositions.

Key players in anti-influenza antibody compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to anti-influenza antibody compositions

GSK is the leading patent filer for anti-influenza antibody compositions. It offers drugs spanning therapeutic areas such as respiratory, oncology, immuno-inflammation, central nervous system (CNS), metabolic, cardiovascular, dermatology, bacterial infections, viral infections, including HIV, and rare diseases.  GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus, influenza and HPV infections, measles, and bacterial meningitis, among others.

In terms of application diversity, HLB Science is the top company, followed by Cidara Therapeutics and BravoVax. By means of geographic reach, Selecta Biosciences holds the top position. While Toko Pharmaceutical Industrial and Catalent are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.